ERBB2 and triple-negative breast carcinoma: Several studies have suggested that single HR-positive tumors without human epidermal growth factor receptor 2 (HER2) overexpression have aggressive clinical features and poorer survival than double HR-positive without HER2 overexpression tumors and triple-negative breast cancer [1].